Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) in Prague, Czech Republic. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham and a Qnexa investigator, will deliver an oral presentation on Saturday, May 15 entitled: "Weight Loss With Controlled-Release PHEN/TPM Drives Improvement in Comorbidities in Overweight and Obese Subjects."

"The CODHy clinical congress is an excellent opportunity for us to share the potential of Qnexa with the global medical community," stated Wesley Day, vice president, clinical development at VIVUS. Dr. Garvey's presentation illustrates the promise of Qnexa for the treatment of obesity and its effect on weight-related co-morbidities, including diabetes and high blood pressure. There is mounting clinical and scientific evidence solidifying the link between obesity and important cardiovascular and metabolic disease.  We are pleased to be able to share this exciting data at an international meeting."

Following are details about the upcoming presentation: